CUREAPP
2.12.2020 10:34:52 CET | Business Wire | Press release
CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Kohta Satake) has announced that CureApp SC Nicotine Addiction Treatment App and CO Checker (hereafter, CureApp SC) – a treatment app (digital therapeutic) targeting nicotine addiction – is now covered by Japan’s public healthcare insurance system as of December 1, 2020, following a period of clinical trials and regulatory approval.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130006039/en/
This marks the first case of a digital therapeutics application being covered by the insurance, as well as the first time that a digital therapeutic in the field of smoking cessation treatments has been covered by a country’s national health insurance system in the world. Patients diagnosed with nicotine addiction at a medical institution are eligible for insurance reimbursement when a doctor prescribes CureApp SC. Under this scheme, patients spend less than 30% of the cost of this product.
Current Japanese public health insurance system and the implication of the approval
Japan has a universal health insurance system that gives all residents the freedom to choose treatment locations. It also enables them to receive the same level of healthcare at a low cost. However, due to the broad scope of such a system – with coverage provided for all residents – the criteria applied for digital therapeutics and other new forms of treatments to receive approval as insured treatments are particularly strict. Therefore, a new treatment to receive such approval has been thought to be significantly difficult compared to do so from private insurance companies. Amidst these circumstances, CureApp has succeeded in leveraging its unique strengths to usher in a new era of treatment, and the achievement has been widely reported by Japanese media.
About CureApp, Inc.
CureApp, founded in 2014 by two physicians, is the leading digital therapeutics company headquartered in Tokyo, Japan. We develop evidence-based software programs in therapeutic areas such as nicotine addiction (regulatory-approved/reimbursed), hypertension (completing phase III trial), Non-Alcoholic Steatohepatitis, NASH, (under clinical trial), alcohol reduction (under clinical trial), and cancer management (in partnership with DAIICHI SANKYO COMPANY). CureApp is the first company in the world to show clinical evidence in a randomized clinical trial, receive regulatory approval and reimbursement under universal healthcare coverage.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130006039/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 07:00:00 CEST | Press release
World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin1 Results show that skin quality has an impact on quality of life for 85% of people, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality1 In response to clinicians’ calls for a universal assessment tool to help address these concerns, Galderma supported leading experts in the development of the Skin Quality Assessment Scale; a holistic, science-based tool to evaluate skin quality comprehensively and guide personalized, long-term treatment planning2 At Galderma, we champion skin quality by providing insights, tools, and solutions to better understand and address a wide spectrum of concerns, helping people take pride and feel comfortable in their own skin at e
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 04:00:00 CEST | Press release
Clinical evidence–backed postbiotic supports mood and well-being with formulation flexibility for diverse applications Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing aw
Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 02:00:00 CEST | Press release
Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom